60 Spam-Free Article(s) Found
Sort:
Relevance
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
MRK Merck & Company, Inc. $70.42 $187.28B N/A
Article Searches
Lilly Announces Tradjenta Cardiovascular Outcome Study Data http://www.zacks.com/stock/news/427738/lilly-announces-tradjenta-cardiovascular-outcome-study-data?cid=CS-ZC-FT-427738 Jun 11, 2019 - Tradjenta leads to fewer events of hypoglycemia and modest weight reduction in type II diabetes patients compared to Sanofi's Amaryl.
Boost Your Portfolio's Health With These 3 Big Drug Stocks http://www.zacks.com/stock/news/428332/boost-your-portfolios-health-with-these-3-big-drug-stocks?cid=CS-ZC-FT-428332 Jun 12, 2019 - The large-cap pharma industry is doing well in 2019. Here are three stocks from the space that investors may consider betting on.
Novartis Reports Data on Cosentyx for Psoriatic Arthritis http://www.zacks.com/stock/news/428752/novartis-reports-data-on-cosentyx-for-psoriatic-arthritis?cid=CS-ZC-FT-428752 Jun 12, 2019 - Novartis (NVS) announces new data on psoriatic arthritis drug, Cosentyx.
Alkermes Initiates Monothearpy Expansion Phase of ALKS 4230 http://www.zacks.com/stock/news/429125/alkermes-initiates-monothearpy-expansion-phase-of-alks-4230?cid=CS-ZC-FT-429125 Jun 13, 2019 - Alkermes (ALKS) initiates monotherapy expansion phase of ALKS 4230 to treat patients with renal cell carcinoma or melanoma.
3 Big Pharma Stocks to Buy Right Now http://www.zacks.com/stock/news/429850/3-big-pharma-stocks-to-buy-right-now?cid=CS-ZC-FT-429850 Jun 14, 2019 - These big pharma stocks all have a Zacks Rank #2 or better.
Agilent Announces Receipt of FDA Approval for pharmDX Assay http://www.zacks.com/stock/news/429945/agilent-announces-receipt-of-fda-approval-for-pharmdx-assay?cid=CS-ZC-FT-429945 Jun 14, 2019 - Agilent (A) receives approval on the expanded use of its PD-L1 IHC 22C3 pharmDx assay.
Novartis (NVS) Announces Promising Data on Tasigna & Hyrimoz http://www.zacks.com/stock/news/430687/novartis-nvs-announces-promising-data-on-tasigna-hyrimoz?cid=CS-ZC-FT-430687 Jun 17, 2019 - Novartis (NVS) announces positive data on CML drugs and biosimilar Hyrimoz.
AstraZeneca/Merck's Lynparza Wins EU Nod for First-Line Use http://www.zacks.com/stock/news/431009/astrazeneca-mercks-lynparza-wins-eu-nod-for-first-line-use?cid=CS-ZC-FT-431009 Jun 18, 2019 - AstraZeneca (AZN) and Merck's PARP inhibitor, Lynparza, gets approval in EU as a front-line therapy for BRCA-mutated advanced ovarian cancer.
Novo Nordisk's Victoza Gets FDA Nod for Pediatric Patients http://www.zacks.com/stock/news/431041/novo-nordisks-victoza-gets-fda-nod-for-pediatric-patients?cid=CS-ZC-FT-431041 Jun 18, 2019 - Novo Nordisk's (NVO) Victoza gets FDA approval for the treatment of pediatric patients aged 10 years or older with type II diabetes.
Are You Looking for a High-Growth Dividend Stock? Merck (MRK) Could Be a Great Choice http://www.zacks.com/stock/news/432705/are-you-looking-for-a-high-growth-dividend-stock-merck-mrk-could-be-a-great-choice?cid=CS-ZC-FT-432705 Jun 21, 2019 - Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.

Pages: 123456

<<<Page 6